Highlights
Montefiore Einstein Comprehensive Cancer Center
Montefiore Einstein Comprehensive Cancer Center treats more than 200 types of cancer, providing highly specialized and compassionate access and care to people in the Bronx, Westchester, and lower Hudson Valley. New visionary leadership has initiated stronger integration of clinical care and clinical/translational research to accelerate transformational scientific discoveries and treatment breakthroughs—improving lives.
DATA & STATISTICS
By the numbers
$49M
in research funding, $33 million in philanthropy
1,000+
patients enrolled in clinical research studies
400
papers published annually in high impact peer-reviewed journals
200+
types of cancer treated
Team News
Additions to our distinguished faculty
Innovations and Achievements
Pioneering the future of treatment and care
Research Review
Improving care and outcomes through research
We continue to publish on a wide variety of topics, including CAR T-cell therapies, new cancer therapies and the impact of COVID-19 on cancer patients.
Clinical Trials
Advancing care through clinical trials
We focus on clinical research studies for the types of cancers that most commonly affect our community—lung cancer, colorectal cancer, cervical cancer, prostate cancer—and more than 80% of patients enrolled on Montefiore Einstein Comprehensive Cancer Center clinical trials are from underrepresented groups. However, our clinical investigators are conducting research in many other types of cancer as well and have focused recently on early-phase clinical trials and greater inclusion of females (now over 55%) and patients from across the lifespan (pediatric patients under the age of 18 as well as patients over age 65).
Highlights from our current 300+ active clinical trials include:
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Brendon M Stiles
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Yvonne Saenger
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Chaoyuan Kuang
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Ioannis Mantzaris
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Haiying Cheng
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Ana Acuna-Villaorduna
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Mendel Goldfinger
Expanded Access
Access matters. We are located in the Bronx, the northernmost of the five counties that comprise New York City, and we are rapidly expanding the number of locations where people can easily be seen throughout the Tristate area—no matter what the level of income, cancer risk, or cancer diagnosis.
Patient referrals
At Montefiore Einstein Comprehensive Cancer Center, we know providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.
Contact us
Anne McDarby
Associate Director, Network Program Management
Montefiore Einstein Comprehensive Cancer Center
1-718-862-8840 /ext. 460
amcdarby@montefiore.org
Andrea Peirce
Assistant Director, Communications
Montefiore Einstein Comprehensive Cancer Center
andrea.peirce@einsteinmed.edu